Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sarepta Therapeutics Inc (SRPT)
Assess today's live Sarepta Therapeutics Inc (SRPT) share price, performance and insights using our live NASDAQ: SRPT stock exchange data.
Analyse the historical data and Sarepta Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Sarepta share price buy/sell indicators using real-time data (or discuss the Sarepta (SRPT) stock price today with other investors in the Sarepta NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ SRPT share price (ISIN: US8036071004) to enhance your trading decisions with our free investment tools and resources.
What Is the Sarepta Therapeutics Inc Share Price Today?
The Sarepta share price today is 16.76.
What Is the Stock Symbol for Sarepta Therapeutics Inc
The stock symbol (or 'ticker') for Sarepta Therapeutics Inc is "SRPT."
What Stock Exchange Does Sarepta Therapeutics Inc Trade On?
Sarepta Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sarepta Therapeutics Inc a Good Stock to Buy?
Determining whether Sarepta Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Sarepta Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Sarepta share price buy/sell indicators using real-time data (or discuss the Sarepta (SRPT) stock price today with other investors in the Sarepta NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ SRPT share price (ISIN: US8036071004) to enhance your trading decisions with our free investment tools and resources.
What Is the Sarepta Therapeutics Inc Share Price Today?
The Sarepta share price today is 16.76.
What Is the Stock Symbol for Sarepta Therapeutics Inc
The stock symbol (or 'ticker') for Sarepta Therapeutics Inc is "SRPT."
What Stock Exchange Does Sarepta Therapeutics Inc Trade On?
Sarepta Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sarepta Therapeutics Inc a Good Stock to Buy?
Determining whether Sarepta Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.46
17.26
52 wk Range
10.42
107.77
SRPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.4617.26
52 wk Range
10.42107.77
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SRPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
21.04
Upside
+25.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Sarepta Company Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics Inc SWOT Analysis
Gene Therapy Setbacks | Delve into Sarepta's challenges with Elevidys, including safety concerns and regulatory hurdles, impacting its market position and financial outlook |
Pipeline Potential | Explore Sarepta's diverse pipeline beyond DMD, including promising treatments for LGMD and other rare neuromuscular diseases |
Market Dynamics | Uncover Sarepta's competitive landscape, strategic partnerships, and potential threats from emerging therapies in the muscular dystrophy market |
Financial Trajectory | Analyst price targets range from $21 to $210, reflecting diverse views on Sarepta's future prospects amid current challenges and long-term growth potential |
Sarepta Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$3.58 missed forecast of -$1.21, while revenue of $442.9M beat expectations by 16.64% on strong product demand.
- Full-year 2025 revenue reached $2.2B, up 16% YoY, driven by PMO franchise and ELEVIDYS gene therapy performance.
- Company ended year with $954M in cash and investments, generating $330M positive operating cash flow for 2025.
- Management projects positive cash flow and non-GAAP profitability in 2026, focusing on pipeline investments and ELEVIDYS expansion.
- Stock rose 0.32% to $18.90 in aftermarket trading despite EPS miss, as investors focused on revenue beat and improved outlook.
Last Updated: 25/02/2026, 23:18
Read Full TranscriptCompare SRPT to Peers and Sector
Metrics to compare | SRPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | 20.1x | −0.6x | |
PEG Ratio | 0.01 | 0.01 | 0.00 | |
Price/Book | 1.5x | 1.4x | 2.6x | |
Price / LTM Sales | 0.8x | 2.1x | 3.3x | |
Upside (Analyst Target) | 13.4% | 15.8% | 44.8% | |
Fair Value Upside | Unlock | 5.8% | 5.5% | Unlock |
Analyst Ratings
7 Buy
14 Hold
5 Sell
Ratings:
26 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 21.04
(+25.56% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
-3.58 / -1.21
Revenue / Forecast
442.90M / 379.71M
People Also Watch
FAQ
What Is the Sarepta (SRPT) Share Price Today?
The Sarepta stock price today is 16.76 USD.
What Stock Exchange Does Sarepta (SRPT) Trade On?
Sarepta is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Sarepta?
The stock symbol (also called a 'ticker') for Sarepta is "SRPT."
What Is the Current Sarepta Market Cap?
As of today, Sarepta market cap is 1.76B USD.
What Is Sarepta's (SRPT) Earnings Per Share (TTM)?
The Sarepta EPS is currently -7.13 (Trailing Twelve Months).
When Is the Next Sarepta Earnings Date?
Sarepta's next earnings report will be released on 06/05/2026.
Is SRPT a Buy or Sell From a Technical Analyst Perspective?
Based on today's Sarepta moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Sarepta Stock Split?
Sarepta has split 1 times. (See the SRPT stock split history page for full effective split date and price information.)
How Many Employees Does Sarepta Have?
Sarepta has 1372 employees.
What is the current trading status of Sarepta (SRPT)?
As of 28/02/2026, Sarepta (SRPT) is trading at a price of 16.76 USD, with a previous close of 17.45 USD. The stock has fluctuated within a day range of 16.46 USD to 17.26 USD, while its 52-week range spans from 10.42 USD to 107.77 USD.
What Is Sarepta (SRPT) Price Target According to Analysts?
The average 12-month price target for Sarepta is 21.04 USD, with a high estimate of 38 USD and a low estimate of 5 USD. 7 analysts recommend buying the stock, while 5 suggest selling, leading to an overall rating of Neutral. The stock has an +25.56% Upside potential.
What Is the SRPT Premarket Price?
SRPT's last pre-market stock price is 17.15 USD. The pre-market share volume is 15,740.00, and the stock has decreased by -0.30, or -1.72%.
What Is the SRPT After Hours Price?
SRPT's last after hours stock price is 16.75 USD, the stock has decreased by -0.01, or -0.06%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.